{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-138224","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.324367+00:00","generated_at":"2026-05-29T01:47:46.098465+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexeo Therapeutics appoints Dr. Kyle Rasbach as CFO effective Dec 18, 2024","bullets":["Dr. Kyle Rasbach appointed CFO; CEO R. Nolan Townsend steps down as principal financial officer.","Initial base salary $480,000, discretionary bonus target 40%; receives 40,875 RSUs and options for 245,250 shares.","Rasbach previously CFO at Zentalis, portfolio manager at Eventide, and analyst at T. Rowe Price and Cowen.","Severance includes 12 months salary, COBRA, and potential equity acceleration; if over $120M financing, unvested equity may continue vesting 24 months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-138224","json":"https://secwatch.observer/filing/0000950170-24-138224.json","markdown":"https://secwatch.observer/filing/0000950170-24-138224.md","text":"https://secwatch.observer/filing/0000950170-24-138224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024138224/0000950170-24-138224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024138224/lxeo-20241218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:47:46.098465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}